Monitoring HCMV in Immunocompromised Patients
Author Information
Author(s): Cariani Elisabetta, Pollara Caterina P, Valloncini Barbara, Perandin Francesca, Bonfanti Carlo, Manca Nino
Primary Institution: Department of Experimental and Applied Medicine, Section of Microbiology, University of Brescia, and A.O. Spedali Civili, Brescia, Italy
Hypothesis
What is the relationship between HCMV DNA levels and pp65 antigenemia in immunocompromised patients?
Conclusion
Both pp65 antigenemia and HCMV DNA load can be useful for monitoring immunocompromised patients, with specific cut-off levels needed for effective treatment.
Supporting Evidence
- HCMV DNA was detected in 106 samples, while pp65 antigen was found in only 3 samples.
- The cut-off HCMV DNA level that best predicted pp65 antigenemia was 11,500 copies/ml.
- HCMV disease was observed in 5 out of 48 patients with active HCMV infection.
Takeaway
Doctors can check for a virus called HCMV in sick patients using two tests, and they need to know the right levels to decide when to start treatment.
Methodology
475 blood samples from 156 immunosuppressed patients were tested for HCMV using pp65 antigenemia and real-time PCR.
Potential Biases
Potential bias in sample selection and interpretation of results due to the nature of the tests used.
Limitations
The study may not generalize to all patient populations due to specific demographics and sample sizes.
Participant Demographics
156 immunosuppressed patients (100 males, 56 females, mean age 44.4 years).
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website